KEYNOTE-001 shows long term benefit from immunotherapy in NSCLC

Three-year results from the KEYNOTE-001 study on pembrolizumab in advanced non-small-cell lung cancer (NSCLC) confirm the known safety and efficacy data for the PD-1 inhibitor. The study, published in The Lancet Respiratory Medicine, comprised 550 patients – about 18% of whom were treatment naïve and the rest had been previously treated. An objective response was ...